Consult your pharmacist to ensure you are not taking Maxalt with these medicines.Do not use this medicine if you have used an MAO inhibitor in the past 14 days, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, or tranylcypromine.Also tell your doctor if you are also taking an antidepressant such as citalopram (Celexa), duloxetine (Cymbalta), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, Symbyax), fluvoxamine (Luvox), paroxetine (Paxil, Pexeva), sertraline (Zoloft), trazodone (Desyrel, Oleptro), venlafaxine (Effexor), or vilazodone (Viibryd).Maxalt will only treat a headache that has already begun. MAXALT should not be prescribed to propranolol-treated pediatric patients who weigh less than 40 kg (88 lb) [see Store MAXALT Tablets at room temperature, 15°C-30°C (59°F-86°F).Store MAXALT-MLT Orally Disintegrating Tablets at room temperature, 15°C-30°C (59°F-86°F).Distributed By: Merck Sharp & Dohme Corp., a subsidiary of MERCK & CO.,INC.,Whitehouse Station, NJ 08889, USA.



infant from MAXALT or MAXALT-MLT or from the underlying maternal condition.Following oral administration of rizatriptan to lactating rats at a dose of 100 mg/kg/day, drug Articles from Britannica Encyclopedias for elementary and high school students. You may report side effects to FDA at 1-800-FDA-1088.Taking Maxalt while you are using certain other medicines can cause This list is not complete. Patients were instructed to treat a moderate to severe headache. Of the 157 births with first-trimester exposure to rizatriptan, 7 infants were born with malformations (relative risk 1.01 [95% CI: 0.40 to 2.08]). When your body sodium is … Its a soft metal, reactive and with a low melting point, with a relative density of 0,97 at 20ºC (68ºF). The safety of treating, on average, more than four headaches in a 30-day period has not been established.Dosing in pediatric patients is based on the patient's body weight. Plasma exposure at the no-effect dose (10 mg/kg/day) for reproductive toxicity was approximately 15 times that in humans at the MRHD.Oral administration of rizatriptan (0, 5, 35, or 250 mg/kg/day) to male rats prior to and during mating resulted in no impairment of fertility or reproductive performance. Maxalt (rizatriptan) is a headache medicine that narrows the blood vessels around the brain.

2-Methyltryptophan is an intermediate in the biosynthesis of the antibiotic thiostrepton, 8 and oligopeptides containing this privileged motif are endothelin receptor …

Sixty-one percent of the patients were Caucasian, and fifty-six percent of the patients were female. In such cases, you should contact your doctor, as you may have to stop taking MAXALT.These are not all the possible side effects of MAXALT. years of age.It is not known if MAXALT is safe and effective in children under 6 years of age.Talk to your doctor before taking this medicine if you have any of the conditions listed above or if you are not sure if you take any of these medicines.MAXALT and other medicines may affect each other causing side effects. Maxalt is a prescription medicine used to treat the symptoms of It is not known if Maxalt is safe and effective in children younger than 6 years of age.Get medical help right away, if you have any of the symptoms listed above.Tell the doctor if you have any side effect that bothers you or that does not go away.These are not all the possible side effects of Maxalt. The maximum daily dose should not exceed 30 mg in any 24-hour period.

Properties of Salt. INDICATIONS. Because the reports include events observed in open studies, the role of MAXALT in their causation cannot be reliably determined. Maxalt (rizatriptan) is a headache medicine that narrows the blood vessels around the brain. Tell your doctor if you are breast-feeding a baby.Maxalt is not FDA-approved for use by anyone younger than 6 years old.Take Maxalt exactly as prescribed by your doctor.

Do not give MAXALT to other people, even if they have the same symptoms that you have. Maxalt tablets: Swallow whole with liquid. All reported events occurred at an incidence ≥1%, or are believed to be reasonably associated with the use of the drug. There was no evidence of an increase in tumor incidence related to rizatriptan in either species. Plasma exposure (AUC) at the no-effect dose (2 mg/kg/day) for adverse effects on postnatal development was similar to that in humans at the MRHD.Oral administration of rizatriptan (0, 5, 100, or 250 mg/kg/day) throughout organogenesis and lactation resulted in There are no data on the presence of rizatriptan or any active metabolites in human milk, or on the effects of rizatriptan on the breastfed infant, or on milk production.Rizatriptan was excreted in rat milk, with levels in milk approximately 6 times those in maternal plasma.The developmental and health benefits of breastfeeding should be considered along with the Of the 310 women who redeemed prescriptions for rizatriptan during the first trimester, 10 had infants with major congenital malformations (OR 1.03 [95% CI: 0.55 to 1.93]), while for the 271 women who redeemed prescriptions for rizatriptan before, but not during, pregnancy, 12 had infants with major congenital malformations (OR 1.48 [95% CI: 0.83 to 2.64]), each compared with the population comparison group.When rizatriptan (0, 2, 10, or 100 mg/kg/day) was administered orally to pregnant rats throughout organogenesis, a decrease in fetal body weight was observed at the highest doses tested. At the mid dose (10 mg/kg/day), which was a no-effect dose for adverse effects on embryofetal development, plasma exposure (AUC) was approximately 15 times that in humans at the maximum recommended human dose (MRHD) of 30 mg/day. You may report side effects to FDA at 1-800-FDA1088.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.